# CompuGroup Medical Denmark A/S

Olof Palmes Allé 44, 8200 Aarhus N

Company reg. no. 24 21 05 29

# **Annual report**

1 January - 31 December 2020

The annual report has been submitted and approved by the general meeting on the 15. June 2021.

Ralph Andreas Körfgen

Chairman

# Contents

	<u>Page</u>
Reports	
Management's statement	1
Independent auditor's report	2
Management's review	
Company's data	5
Management's review	6
Annual Accounts 1 January – 31 December 2020	
Profit and loss account	8
Balance sheet	9
Statement of changes in equity	13
Notes	14
Accounting policies used	22

# Management's statement

The Executive Board and Board of Directors have today considered and adopted the Annual Report of CompuGroup Medical Denmark A/S for the financial year 1 January - 31 December 2020.

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2020 of the Company and of the results of the Company operations for 2020.

In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Aarhus, 15. June 2021

**Managing Director** 

Michael Hein

**Board of directors** 

Ralph Andreas Körfgen

Chairman

Michael Hein

1

#### To the shareholder of CompuGroup Medical Denmark A/S

#### **Opinion**

We have audited the financial statements of CompuGroup Medical Denmark A/S for the financial year 1 January – 31 December 2020 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2020 and of the results of the Company's operations for the financial year 1 January – 31 December 2020 in accordance with the Danish Financial Statements Act.

# **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control, that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

## Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Aarhus, 15. June 2021

**KPMG** 

Statsautoriseret Revisionspartnerselskab CVR no. 25 57 81 98

Michael E. K. Rasmussen

State Authorised Public Accountant

mne41364

# Company data

The Company CompuGroup Medical Denmark A/S

Olof Palmes Allé 44 8200 Aarhus N

Phone: +45 7030 1340

Website: www.cgm.com/dk

Company reg. no.: 24 21 05 29

Domicile: Aarhus

Financial year: 1 January – 31 December

22th financial year

**Board of directors** Ralph Andreas Körfgen, chairman

Michael Hein

Henrik Aase

Managing Director Michael Hein

Auditors KPMG

Statsautoriseret Revisionspartnerselskab

Bredskifte Alle 13

8210 Aarhus V

# Management's review

# Financial highlights

DKKm	2020	2019	2018	2017	2016
Gross profit/loss	64,39	67,23	60,21	54,20	49,33
Ordinary operating profit/loss	29,76	34,46	30,65	27,18	21,15
Profit/loss from financial income and expenses	0,35	0,91	1,34	0,92	0,53
Profit/loss for the year	23,38	27,70	24,65	21,72	16,89
Total assets	58,67	59,26	55,41	48,87	39,10
Investments in property, plant and equipment	0,85	0,47	0,27	0,50	0,63
Equity	37,50	41,12	38,42	35,77	29,04
Current ratio	127%	286%	265%	281%	249%
Return on equity	59%	70%	66%	67%	69%
Solvency ratio	64%	69%	69%	73%	74%
Average number of full-time employees	60	58	54	48	53

Financial ratios are calculated in accordance with the guidelines "Recommendations & Ratios" issued by the Danish Society of Financial Analysts. The financial ratios have been calculated as follows:

Current ratio

Current assets x 100 Short-term debt

Return on equity

Profit from ordinary activities after tax x 100

Average equity

Solvency ratio

Equity ex. non-controlling interests at year end x 100

Total equity and liabilities at year end

## The principal activities of the company

The Company's primary activities have as in previous years been development, sale and consultancy within the IT area of administrative healthcare systems in the primary sector.

#### Development in activities and financial matters

The income statement of the Company for 2020 shows a profit of DKK 23.383.130 and as at 31. December 2020 the balance sheet of the Company shows equity of DKK 37.504.038.

Considering the pandemic, we are pleased with the annual result, which is DKK 4.3 mill lower than 2019 and the fact that we have been able to navigate through the pandemic without having to resort to changes in personnel and without any Covid-19 related cases of sickness among our employees. The DKK 4.3 mill is due to lower revenue, as our customers also were affected by the pandemic. Gross profits decreased slightly due to different priority in using liquidity.

## Uncertainty relating to recognition and measurement

Recognition and measurement in the Annual Report have not been subject to any uncertainty.

## Impact of the Covid-19 pandemic and other events

The fiscal year 2020 was highly impacted by the Covid-19 pandemic, CompuGroup Medical Denmark A/S reacted early and implemented appropriate protective measures for employees and customers thereby being able to avoid any drastic measures or support on aid programs. The Company for the financial year for 2020 has not been affected by any other further unusual events.

#### **Events subsequent to the financial year**

Besides Covid-19, no events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.

## Targets and expectations for the year ahead

At the outset of 2021, the outbreak of the coronavirus, COVID-19, has affected large parts of the world. The outbreak of COVID-19 and the global/Danish precautions to reduce the spread of the virus have had an adverse impact on the Danish economy.

Based on realized figures for 2020 and the revised forecast for 2021, the Company is of the opinion that COVID-19 will still have a severe impact of the Company's financial statements for 2021. We will steer and act with alacrity and be as proactive as possible to avoid impact above what has been seen in 2020 and we expect only our service and delivery business to be affected, though we have become relatively good at adapting this in a manner that will not expose employees or customers to any unnecessary risks.

Expected net result in 2021 is between 25 to 30 mill. DKK. The increase of net result compared to 2020, is primarily due to an acquisition made in December 2020.

Note	<u>.</u>	2020_	2019
	Gross Profit	64.389.021	67.232.587
1	Staff Costs	-33.403.252	-31.151.750
	Depreciation, amortization and writedown relating to tangible and intangible fixed assets	-1.225.322	-1.624.318
	Results before net financials	29.760.447	34.456.519
	Other financial income	352.064	1.079.994
	Other financial cost	367_	170.600
	Results before tax	30.112.144	35.365.916
2	Tax on ordinary results	-6.729.014	-7.661.158
3	Results for the Year	23.383.130	27.704.758

# **Balance sheet 31 December**

# All amounts in DKK

## **Assets**

<u>Note</u>	2020	2019_
Fixed Assets		
4 Completed Development Projects	0	0
5 Knowhow	0	0
6 Goodwill	26.812.556	9.010.540
7 Licenses, concessions, patents	122.432	233.208
Intangible fixed assets in total	26.934.988	9.243.748
8 Other plants, operating assets, fixtures and furniture	225.979	164.268
9 Furniture and office equipment	624.572	304.867
Tangible fixed assets in total	850.551	469.135
Finance lease	4.462.820	2.224.748
10 Other debtors	1.656.229	1.086.979
Financial fixed asset total	6.119.048	3.311.727
Fixed assets in total	33.904.587	13.024.610

# **Balance sheet 31 December**

# All amounts in DKK

# **Assets**

<u>Note</u>		2020	2019
	Current Assets		
	Manufactured goods and trade goods	361.908	638.974
	Inventories in total	361.908	638.974
	Trade debtors	3.997.465	8.117.205
	Amounts owed by group enterprises	4.716.437	605.077
	Other debtors	305.234	352.221
	Corporate tax	989.450	0
	Finance lease	1.787.035	700.625
	Deferred expenses	1.567.185	1.623.937
	Receivables in total	13.362.806	11.399.064
	Cash at bank and in hand	11.038.865	34.197.068
	Current Assets in Total	24.763.578	46.235.107
	Total Assets	58.668.165	59.259.717

# **Balance sheet 31 December**

# All amounts in DKK

# **Equity and Liabilities**

<u>Note</u>		2020_	2019
	Equity		
11	Contributed capital	5.500.000	5.500.000
	Results brought forward	9.004.038	8.620.907
	Proposed dividend for the financial year	23.000.000	27.000.000
	Equity in total	37.504.038	41.120.907
	Provisions		
12	Provisions for deferred tax	1.610.450	755.896
	Provisions in total	1.160.450	755.896
	Liabilities		
	Other liabilities	0	1.205.327
	Non-current liabilities other than provisions in total	0	1.205.327

# **Equity and Liabilities**

	Equity and Liabilities in Total	58.668.165	59.259.717
	Liabilities in Total	21.164.128	18.138.810
	Short-term liabilities in total	19.553.678	16.177.587
	Deferred income	3.917.325	1.303.883
	Other liabilities	8.322.384	5.224.835
	Corporate Tax	0	5.393.646
	Debt to group enterprises	5.189.462	1.133.766
	Trade Creditors	2.124.507	3.121.457
<u>Note</u>		2020_	2019_

# 13 Contingencies

# 14 Related parties

	Contributed capital	Results brought forward	Proposed dividend for the financial year	In total
Equity 1 January 2019	5.500.000	7.916.149	25.000.000	38.416.149
Dividend for the financial year	0	0	-25.000.000	-25.000.000
Profit or loss for the year brought forward	0	704.758	27.000.000	27.704.758
Equity 1 January 2020	5.500.000	8.620.907	27.000.000	41.120.907
Dividend for the financial year	0	0	-27.000.000	-27.000.000
Profit or loss for the year brought forward	0_	383.131	23.000.000	23.383.131
Equity 31 December 2020	5.500.000	9.004.038	23.000.000	37.504.038

All amounts in DKK				
		2020	2019	
1.	Staff Costs			
	Salaries and Wages	31.755.946	29.780.949	
	Pension Costs	1.226.759	1.119.336	
	Other costs for social security	420.547	251.464	
		33.403.252	31.151.750	
	Average number of employees	60	58_	
2	Pursuant to section 98b (3) of the Danish Financial Staten disclosed executive remuneration.	nents Act, the	Company has not	
2.	Tax on ordinary results			
	Tax of the results for the year, parent company	5.874.550	7.717.556	
	Adjustment for the year of deferred tax	854.554	135.788	
	Adjustment of tax for previous years		-192.186	
		6.729.014	7.661.158	
3.	Proposed distribution of the results:			
	Dividend for the financial year	23.000.000	27.000.000	
	Allocated from results brought forward	383.130	704.758	
	Distribution in total	23.383.130	27.704.758	

		31.12.2020	31.12.2019
4.	Completed development projects		
	Opening balance at 01 January 2020	3.881.330	3.881.330
	Balance at 31 December 2020	3.881.330	3.881.330
	Amortisation and write-down 1 January 2020	-3.881.330	-3.881.330
	Amortisation and write-down 31 December 2020	-3.881.330	-3.881.330
	Net book value 31 December 2020	0_	0
		31.12.2020	31.12.2019
5.	Knowhow		
	Opening balance at 01 January 2020	2.283.606	2.283.606
	Balance at 31 December 2020	2.283.606	2.283.606
	Amortisation and writedown 1 January 2020	-2.283.606	-2.283.606
	Amortisation and writedown 31 December 2020	-2.283.606	-2.283.606
	Net book value 31 December 2020	0	0

		31.12.2020	31.12.2019
6.	Goodwill		
	Opening balance at 01 January 2020	28.366.036	28.366.036
	Additions	18.568.769	0
	Balance at 31 December 2020	46.934.805	28.366.036
	Amortisation and write-down 1 January 2020	-19.355.496	-18.321.983
	Amortisation for the year	-766.754	-1.033.512
	Amortisation and writedown 31 December 2020	-20.122.250	-19.355.496
	Net book value 31 December 2020	26.812.556	9.010.540
		04.40.0000	04.40.0040
		31.12.2020	31.12.2019
7.	Licenses, concessions, patents		
	Opening balance at 01 January 2020	9.548.153	9.548.153
	Additions	188.751	0
	Balance at 31 December 2020	9.736.904	9.548.153
	Amortisation and write-down 1 January 2020	-9.314.945	-8.986.927
	Amortisation for the year	-299.528	-328.018
	Amortisation and writedown 31 December 2020	-9.614.473	-9.314.945
	Net book value 31 December 2020	122.432	233.208

		31.12.2020	31.12.2019
8.	Other Plants, Operating Assets, and Fixtures and Furniture		
	Opening balance at 01 January 2020	5.538.068	5.749.913
	Additions during the year	148.349	138.155
	Disposals during the year	-15.000	-350.000
	Balance at 31 December 2020	5.671.417	5.538.068
	Depreciation and writedown 01 January 2020	-5.373.800	-5.748.871
	Adjustment to starting balance	0	80.928
	Depreciation for the year	-86.638	-55.857
	Depreciation, amortisation and writedown for the year, assets disposed of	15.000	350.000
	Depreciation and writedown 31 December 2020	-5.445.438	5.373.800
	Net book value 31 December 2020	225.979	164.268

		DKK

All	amounts in DAA		
		31.12.2020	31.12.2019
9.	Furniture and office equipment		
	Opening balance at 01 January 2020	3.683.243	3.438.489
	Additions during the year	392.108	244.754
	Balance at 31 December 2020	4.075.351	3.683.243
	Depreciation and write-down 01 January 2020	-3.378.377	-3.171.446
	Depreciation for the year	-72.401	-206.931
	Depreciation and write-down 31 December 2020	-3.450.778	-3.378.377
	Net book value 31 December 2020	624.572	304.867
		<u>31.12.2020</u>	<u>31.12.2019</u>
10.	Other Debtors		
	Opening balance at 01 January 2020	1.086.979	1.086.979
	Additions during the year	569.250	0
	Balance at 31 December 2020	1.656.229	1.086.979
	Net book value 31 December 2020	1.656.229	1.086.979
	D. marta I. a.		
	Reported as: Deposits	1.656.229	1.086.979

# 11. Contributed Capital

The share capital consists of 5,500 shares of a nominal value of DKK 1,000. No shares carry any special rights.

12.	Deferred Tax	2020	2019_
	Deferred tax at 1 January	755.896	620.108
	Deferred tax adjustment for the year in the income statement	854.554	135.788_
		1.610.450	755.896

# 13. Contingencies

**Contingent Liabilities** 

Lease obligations under operating leases.

Total future lease payments:

	31.12.2020	31.12.2019
	DKK in thousands	DKK in thousands
Within 1 year	891	314
More than 1 year	1.094	979
Operating lease in Total	1.985	1.293
Within 1 year	1.981	4.400
More than 1 year	11.512	0
Rental lease, period of non-terminability up to 7,5 years	13.493	4.400

#### 14. Related Parties

## Control

Profdoc AS, Lysaker torg 15, 1366 Lysaker, Norway.

Profdoc AS holds the majority of the contributed capital in the Company.

CompuGroup Medical Denmark A/S is part of the consolidated statement of CompuGroup Medical SE & Co. KGaA, Germany, which is the smallest and largest group, in which the company is included as a subsidiary.

The consolidated financial statements of CompuGroup Medical SE & Co. KGaA can be obtained by contacting CompuGroup Medical SE & Co. KGaA using the following address:

CompuGroup Medical SE & Co. KGaA
Maria Trost 21,
56070 Koblenz
Germany
<a href="https://www.cgm.com">https://www.cgm.com</a>

#### **Notes**

# Relationships

Holding Company Profdoc AS

Fellow Subsidiaries CompuGroup Medical Norway AS

CompuGroup Medical Sweden AB CompuGroup Medical SE & Co.

**KGaA** 

CompuGroup Medical Deutschland AG CompuGroup Medical France SAS

CompuGroup Medical IT Solutions+Services

CompuGroup Medical Nederland BV

Members of key management Ralph Andreas Körfgen

Henrik Aase Michael Hein

# **Related Party Balances**

Payables and receivables from related parties are disclosed in the balance sheet.

# **Related Party Transactions**

Sales of goods/services to a subsidiary: 6.014.087 DKK

Purchases of goods from a subsidiary: 4.105.143 DKK

## Accounting policies used

The annual report of CompuGroup Medical Denmark A/S for 2020 has been prepared in accordance with the provisions applying to reporting class C medium-sized entities under the Danish Financial Statements Act.

The accounting policies used are unchanged compared to last year, and the annual accounts are presented in Danish kroner (DKK).

A few restatements have been made of the comparative figures as a result of reclassications.

#### Omission of cash flow statement

Pursuant to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The Company's cash flows are included in the cash flow statement in the consolidated financial statements of CompuGroup Medical SE & Co. KGaA, Maria Trost 21, 56070 Koblenz, Germany, CVR no. HRB 27430.

#### Recognition and measurement in general

Income is recognised in the profit and loss account concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs, these including depreciation, amortisation, write-down, provisions, and reversals which are due to changes in estimated amounts previously recognised in the profit and loss account are recognised in the profit and loss account.

Assets are recognised in the balance sheet when the company is liable to achieve future, financial benefits and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the company is liable to lose future, financial benefits and the value of the liability can be measured reliably.

At the first recognition, assets and liabilities are measured at cost. Later, assets and liabilities are measured as described below for each individual accounting item.

At recognition and measurement, such predictable losses and risks are taken into consideration, which may appear before the annual report is presented, and which concerns matters existing on the balance sheet date.

# Translation of foreign currency

Transactions in foreign currency are translated by using the exchange rate prevailing at the date of the transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under net financials.

#### Accounting policies used

Debtors, creditors, and other monetary items in foreign currency are translated by using the closing rate. The difference between the closing rate and the rate at the time of the occurrence or the recognition in the latest annual accounts of the amount owed or the liability is recognised in the profit and loss account under financial income and expenses.

# The profit and loss account

#### **Gross profit**

The gross profit comprises the net turnover, changes in inventories of finished goods and work in progress, work performed for own purposes and capitalised, other operating income, and external costs.

The net turnover comprises the value of services provided during the year, including outlay for customers less VAT and price reductions directly associated with the sale.

The turnover is recognised in the profit and loss account when the sale has been completed. This is generally considered to be the case when:

- The service has been provided before the end of the financial year
- There is a binding sales agreement
- The sales price has been determined
- The payment has been received, or it can with reasonable assurance be expected to be received.

Hereby, it is ensured that recognition does not take place until the total income and costs as well as the scope of completion on the balance sheet date can be determined reliably, and when it is likely that the economic benefits, including payments, will be received by the enterprise.

Costs of sales includes costs for the purchase of raw materials and consumables less discounts and changes in inventories.

Other operating income comprise accounting items of secondary nature in proportion to the principal activities of the enterprise, including gains on disposal of intangible and tangible fixed assets.

Other external costs comprise costs for distribution, sales, advertisement, administration, premises, loss on debtors, and operational leasing costs.

#### Staff costs

Staff costs include salaries and wages including holiday allowances, pensions and other costs for social security etc. for staff members less public reimbursements.

#### Depreciation, amortisation and writedown

Depreciation, amortization and writedown comprise depreciation on, amortisation of and writedown relating to intangible and tangible fixed assets respectively.

#### **Net financials**

Net financials comprise interest, financial income regarding finance leases, realised and unrealised capital gains and losses concerning financial assets and liabilities, amortisation of financial assets and liabilities, additions and reimbursements under the Danish tax prepayment scheme, etc. Financial income and expenses are recognised in the profit and loss account with the amounts that concerns the financial year.

## Tax of the results for the year

The tax for the year comprises the current tax for the year and the changes in deferred tax, and it is recognised in the profit and loss account with the share referring to the results for the year and directly in the equity with the share referring to entries directly on the equity.

## The balance sheet

## Intangible fixed assets

# Development projects, knowhow, patents, and licenses

Development costs and internally generated rights are recognised in the profit and loss account as costs in the acquisition year.

Patents and licenses are measured at cost with deduction of accrued amortisation. Patents are amortised on a straight-line basis over the remaining patent period, and licenses are amortised over the contract period, however, for a maximum of 5 years.

Gain and loss from the sale of development projects, patents, and licenses are measured as the difference between the sales price with deduction of sales costs and the book value at the time of the sale. Gain or loss are recognised in the profit and loss account as other operating income or other operating expenses respectively.

## Goodwill

Goodwill is amortised over its estimated useful life, which is determined on the basis of the management's experience with the individual business areas. Goodwill is amortised on a straight-line basis over the amortisation period, which is assessed at max. 18 years. The amortisation period is determined on the basis of an expected payback period, being the longer for strategical acquires with a strong market position and an expected long-term earnings profile.

## Accounting policies used

# **Tangible fixed assets**

Tangible fixed assets are measured at cost with deduction of accrued depreciation and write-down.

The cost comprises the acquisition cost and costs directly attached to the acquisition until the time when the asset is ready for use.

The basis of depreciation is cost with deduction of any expected residual value after the end of the useful life of the asset. The depreciation period and the residual value are determined at the acquisition date and reassessed annually. If the residual value exceeds the book value, the depreciation discontinues.

Depreciation takes place on a straight-line basis and based on an evaluation of the expected useful life:

Other plants, operating assets, fixtures and furniture 3-5 years

Furniture and office equipment 3-5 years

If the depreciation period or the residual value is changed, the effect on depreciation will in the future be recognized as a change in the accounting estimates.

## **Leasing contracts**

Leases for fixed assets that transfer substantially all risks and rewards incident to ownership to the lessee (finance leases) are recognised in the balance sheet as a receivable under non-current assets with its long-term portion and under current assets with its short-term portion. On initial recognition, assets are measured at cost, equivalent to the lower of fair value and the net present value of future lease payments.

The recognised value of the lease is written down in line with instalments received. The interest element of the lease payment is to be recognised in the income statement over the term of the lease.

#### Write-down of fixed assets

The book values of both intangible and tangible fixed assets as well as equity investments in subsidiaries and associated enterprises are subject to annual impairment tests in order to disclose any indications of impairment beyond those expressed by amortisation and depreciation respectively.

If indications of impairment are disclosed, impairment tests are carried out for each individual asset or group of assets respectively. Writedown takes place to the recoverable amount, if this value is lower than the book value.

#### Accounting policies used

#### **Inventories**

Inventories are measured at cost on basis of the FIFO method. In case the net realisable value of the inventories is lower than the cost, writedown takes place to this lower value.

The cost for trade goods, raw materials, and consumables comprises the acquisition cost with the addition of the delivery costs.

The net realisable value for inventories is recognised as the market price with deduction of completion costs and selling costs. The net realisable value is determined taking into consideration the negotiability, obsolescence, and development of the expected market price.

#### **Debtors**

Debtors are measured at amortised cost which usually corresponds to face value. In order to meet expected losses, writedown takes place at the net realisable value.

### **Deferred expenses**

Deferred expenses recognized under assets comprise incurred costs concerning the next financial year. This includes costs such as rent and insurance.

#### Cash at bank and in hand

Available funds comprise cash at bank and in hand.

## **Equity**

## **Dividends**

Dividends are expected to be distributed for the year is recognized as a separate item under the equity. Proposed dividends are recognized as a liability at the time of approval by the general meeting (the time of declaration).

## Corporate tax and deferred tax

Current lax receivable and lax liabilities are recognized in the balance sheet at the amount calculated on the basis of the expected taxable income for the year adjusted for tax on previous years' taxable income and prepaid taxes.

Tax receivable and tax liabilities are set off to the extent that legal right of set-off exists and if the items are expected to be settled net or simultaneously.

Deferred tax is measured on the basis of all temporary differences in assets and liabilities with a balance sheet focus.

Deferred tax assets, including the tax value of tax eligible for carry over, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set off in deferred tax liabilities within the same legal tax unit.

Deferred tax is measured based on the tax rules and tax rates applying under the legislation on the balance sheet date and prevailing when the deferred tax is expected to be released as current tax.

#### Liabilities

Liabilities are measured at amortised cost which usually corresponds to the nominal value.

Accounting policies used			